Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BeyondSpring Inc. (BYSI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7000+0.1000 (+3.85%)
At close: 04:00PM EST
2.7000 0.00 (0.00%)
After hours: 07:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing Rules

    NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on December 29, 2022, the Company received a written notification (the “Notification Letter on Compliance”) from Nasdaq that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). In the Notification L

  • Simply Wall St.

    Individual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as well

    Every investor in BeyondSpring Inc. ( NASDAQ:BYSI ) should be aware of the most powerful shareholder groups. And the...

  • Benzinga

    Why Are BeyondSpring Shares Trading Higher?

    BeyondSpring Inc (NASDAQ: BYSI) presented data from the lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients. In summary, data from 101 and 103 studies, plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN, and duration of severe neutropenia (DSN) compared to the control. There was a reduction in mean DSN of >1 day for plinabulin vs. control. In the 105 study, NSCLC pts with at least one febrile neutropen

Advertisement
Advertisement